



Life Sciences & Health Care Quarterly update

Q1 2019

Health systems strategic focus on analytics⁽¹⁾

The health care industry is counting on analytics to help it overcome many of its challenges and unlock value from evolving and new data sources.

Analytics is a necessary capability to help shift to value-based payment models and can help health systems deliver higher quality of care while improving operations and lowering costs. It is also important for strategies and initiatives that depend on data mining—such as understanding social determinants of health and the importance of customer experience and preferences. Heading into the future, data analytics is expected to be one of the backbones for health systems seeking to use emerging technologies such as artificial intelligence (AI) and robotic process automation (RPA) to transform their care delivery or workforce.

Health systems are increasingly making analytics a priority, as their planning, governance, and investments show. They recognize its importance for their strategies today and even more so for the future. The Deloitte Center for Health and Solutions measured changes in analytics maturity across four areas, including having: (i) a defined strategy and vision; (ii) a dedicated analytics department; (iii) chief analytics leadership; and (iv) a formal data governance process.

Investment into analytics⁽²⁾

The Deloitte Center for Health Solutions (DCHS) conducted research to see if health systems have increased their investments and use of analytics for clinical, operational, and financial functions. In late 2018, DCHS surveyed 56 chief information officers (CIOs), chief technology officers (CTOs), and chief analytics executives at health systems in order to understand today's landscape and compare it with findings from the 2015 survey on the same topic.

When it comes to analytics, health systems in 2018 are more likely to have:

- Defined strategies and visions (70 percent in 2018 vs. 40 percent in 2015);
- Dedicated departments (88 percent in 2018 vs. 76 percent in 2015); and
- Centralized governance models (68 percent in 2018 vs. 58 percent in 2015).

C-suite role⁽³⁾

Organizations are now more likely to have a C-suite role dedicated to analytics (30 percent had a chief analytics officer in 2018 vs. 12 percent in 2015).

Organizational strategy⁽⁴⁾

84 percent of executives say that analytics will be extremely important for their organization's strategies in three years, compared to 36 percent who say analytics are extremely important today.

Recent relevant M&A activity

Pharmagest Group acquires 15 percent stake of Embleema:

On January 7, 2019, France-based Pharmagest Group, a pharmacy technology leader, acquired a 15 percent stake of Embleema, a French-American company specializing in healthcare blockchain technology, for \$3.7 million. This strategic partnership is fully aligned with Pharmagest Group's strategy of placing the patient at the heart of the healthcare system and offers patients a way to participate in medical research.⁽⁵⁾

HCA Healthcare invests in Digital Reasoning Systems, Inc.:

On March 21, 2018, Tennessee-based HCA Healthcare, Inc., a leading health care services company, invested in Digital Reasoning Systems, Inc., a Tennessee-based company specializing in data analytic solutions, during a \$50.0 million funding round. This capital will be used to accelerate key artificial intelligent innovations across speech analytics, natural language understanding and machine education, and expand its go-to-market capacity.⁽⁶⁾

In this update

- Master protocols offer a collaborative and cost-efficient solution to current drug development methods.

Also:

- Selected Recent Life Sciences & Health Care (LSHC) M&A Transactions
- LSHC Sector Breakdown and Analysis
- Selected Macroeconomic and Sector Data

Who we are

Deloitte Corporate Finance LLC (DCF) is a leading global middle market M&A advisor. DCF's professionals have extensive knowledge of and experience in the Life Sciences & Health Care space.

LSHC contacts

Simon Gisby

Managing Director
sgisby@deloitte.com
+1 (212) 436-2495

Doug Bolt

Managing Director
dbolt@deloitte.com
+1 (704) 731-7219

Jason Porter


Managing Director
jasporter@deloitte.com
+1 (704) 333-0136

Nick Cirignano

Managing Director
nicirignano@deloitte.com
+1 (212) 436-3273

Q1 2019 US LSHC M&A aggregate transaction value ⁽¹⁾⁽ⁱ⁾

Aggregate transaction value (\$ in millions)

**Q1 2019 US LSHC M&A activity deal list ⁽²⁾⁽ⁱ⁾**

Date announced	Status	Sub-sector	Target	Buyer	Size (\$MM) transaction
27-Mar-19	Announced	Managed Health Care	WellCare Health Plans, Inc. (NYSE:WCG)	Centene Corporation (NYSE:CNC)	\$15,620.3
24-Mar-19	Announced	Life Sciences	Brammer Bio, LLC	Thermo Fisher Scientific Inc. (NYSE:TMO)	1,700.0
18-Mar-19	Closed	Medical Devices	PowerVision, Inc.	Alcon Laboratories, Inc.	285.0
14-Mar-19	Announced	Medical Devices	DCP Holding Company	DentaQuest LLC	41.5
12-Mar-19	Announced	Managed Health Care	Osiris Therapeutics, Inc. (NasdaqGM:OSIR)	Smith & Nephew plc (LSE:SN.)	660.5
11-Mar-19	Closed	Medical Devices	Voalte, Inc.	Hill-Rom, Inc.	195.0
5-Mar-19	Announced	Life Sciences	Royalty of Ligand Pharmaceuticals Incorporated	RP Management LLC	827.0
5-Mar-19	Closed	Technology	myoscience, Inc.	Pacira BioSciences, Inc. (NasdaqGS:PCRX)	220.0
5-Mar-19	Closed	Life Sciences	Prescribe Wellness, LLC	Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC)	150.0
27-Feb-19	Announced	Medical Devices	Myonex Therapeutics, Inc.	Sarepta Therapeutics, Inc. (NasdaqGS:SRPT)	165.0
25-Feb-19	Announced	Technology	BioPharma Business of General Electric Company	Danaher Corporation (NYSE:DHR)	21,400.0
25-Feb-19	Announced	Services	Spark Therapeutics, Inc. (NasdaqGS:ONCE)	Roche Holding AG (SWX:ROG)	4,851.2
21-Feb-19	Closed	Life Sciences	Immune Design Corp.	Merck Sharp & Dohme Corp.	296.0

Notes:

i) Only US deals with reported transaction size greater than \$30MM listed.

Q1 2019 US LSHC M&A activity deal list ⁽¹⁾ (i)

Date announced	Status	Sub-sector	Target	Buyer	Size (\$MM) transaction
19-Feb-19	Announced	Life Sciences	All Assets of Permex Therapeutics Holdings, Inc.	Highbridge Capital Management, LLC	75.6
13-Feb-19	Closed	Life Sciences	Auris Health, Inc.	Ethicon US, LLC	5,750.0
12-Feb-19	Announced	Medical Devices	CAS Medical Systems, Inc. (NasdaqCM:CASM)	Edwards Lifesciences Corporation (NYSE:EW)	108.2
4-Feb-19	Closed	Services	15 Skilled Nursing Facilities	Genesis Healthcare, Inc. (NYSE:GEN); Next Healthcare	204.0
28-Jan-19	Announced	Services	Anatomical Pathology Business of Thermo Fisher Scientific Inc.	PHC Holdings Corporation	1,140.0
28-Jan-19	Closed	Services	Geneva Healthcare, Inc.	BioTelemetry, Inc. (NasdaqGS:BEAT)	65.0
24-Jan-19	Closed	Facilities	Hammes Medical Office Portfolio	Welltower Inc. (NYSE:WELL)	391.0
16-Jan-19	Announced	Life Sciences	Fuse Medical, Inc. (OTCPK:FZMD)	Generex Biotechnology Corporation (OTCPK:GNBT)	34.0
11-Jan-19	Closed	Technology	DataCeutics, Inc.	NAVITAS LIFE SCIENCES LIMITED	45.0
7-Jan-19	Closed	Medical Devices	Loxo Oncology, Inc.	Eli Lilly and Company (NYSE:LLY)	8,013.1
7-Jan-19	Effective	Facilities	Digital PCR Program Assets of Formulatrix, Inc.	QIAGEN N.V. (NYSE:QGEN)	260.0
3-Jan-19	Announced	Facilities	Celgene Corporation (NasdaqGS:CELG)	Bristol-Myers Squibb Company (NYSE:BMJ)	99,553.6

Note:

i) Only US deals with reported transaction size greater than \$30MM listed.

LSHC sector breakdown: financial detail (1)

	Enterprise value (\$MM)	Three-year revenue CAGR	LTM			EV / LTM	
			Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA
Assisted Living / Long-Term Care (4)							
Brookdale Senior Living Inc. (NYSE:BKD)	\$5,376.0	(6.0) %	\$3,521.2	\$534.2	15.2 %	1.5 x	10.1 x
The Ensign Group, Inc. (NasdaqGS:ENSG)	2,931.0	15.0	2,040.7	183.3	9.0	1.4	16.0
Capital Senior Living Corporation (NYSE:CSU)	1,118.3	3.6	457.0	61.2	13.4	2.4	18.3
National HealthCare Corporation (AMEX:NHC)	1,017.7	2.6	978.7	101.0	10.3	1.0	10.1
Median		3.1 %			11.9 %	1.5 x	13.0 x
Hospitals (4)							
HCA Healthcare, Inc. (NYSE:HCA)	\$76,196.8	5.6 %	\$46,677.0	\$8,920.0	19.1 %	1.6 x	8.5 x
Tenet Healthcare Corporation (NYSE:THC)	17,401.1	(0.6)	18,313.0	2,791.0	15.2	1.0	6.2
Universal Health Services, Inc. (NYSE:UHS)	15,945.6	6.0	10,772.3	1,681.6	15.6	1.5	9.5
Community Health Systems, Inc. (NYSE:CYH)	13,787.1	(10.0)	14,155.0	1,452.0	10.3	1.0	9.5
Median		2.5 %			15.4 %	1.2 x	9.0 x
Psychiatric and Behavioral Health (2)							
Acadia Healthcare Company, Inc. (NasdaqGS:ACHC)	\$5,738.0	18.8 %	\$3,012.4	\$571.6	19.0 %	1.9 x	10.0 x
AAC Holdings, Inc. (NYSE:AAC)	376.2	21.9	317.3	31.2	9.8	1.2	12.0
Median		20.4 %			14.4 %	1.5 x	11.0 x
Rehabilitation Facilities (3)							
Encompass Health Corporation (NYSE:EHC)	\$8,474.5	11.1 %	\$4,277.3	\$881.3	20.6 %	2.0 x	9.6 x
Select Medical Holdings Corporation (NYSE:SEM)	5,089.9	11.3	5,081.3	621.8	12.2	1.0	8.2
U.S. Physical Therapy, Inc. (NYSE:USPH)	1,443.0	11.2	449.3	70.1	15.6	3.2	20.6
Median		11.2 %			15.6 %	2.0 x	9.6 x
Surgery Centers (1)							
Surgery Partners, Inc. (NasdaqGS:SGRY)	\$2,850.4	23.7 %	\$1,771.5	\$321.7	18.2 %	1.6 x	8.9 x
Median		23.7 %			18.2 %	1.6 x	8.9 x
Clinical Laboratories (3)							
Laboratory Corporation of America Holdings (NYSE:LH)	\$21,160.7	10.0 %	\$11,333.4	\$1,907.3	16.8 %	1.9 x	11.1 x
Quest Diagnostics Incorporated (NYSE:DGX)	16,016.4	0.2	7,531.0	1,534.0	20.4	2.1	10.4
Chemed Corporation (NYSE:CHE)	5,265.0	4.9	1,782.6	278.4	15.6	3.0	18.9
Median		2.5 %			18.0 %	2.5 x	14.7 x
Diagnostic Imaging (1)							
RadNet, Inc. (NasdaqGM:RDNT)	\$1,315.0	6.4 %	\$975.1	\$106.3	10.9 %	1.3 x	12.4 x
Median		6.4 %			10.9 %	1.3 x	12.4 x
Dialysis Services (3)							
Fresenius SE & Co. KGaA (DB:FRE)	\$50,924.8	6.7 %	\$38,390.2	\$6,481.6	16.9 %	1.3 x	7.9 x
DaVita Inc. (NYSE:DVA)	18,851.0	4.6	11,412.2	2,080.9	18.2	1.7	9.1
American Renal Associates Holdings, Inc. (NYSE:ARA)	700.8	9.1	817.2	174.1	21.3	0.9	4.0
Median		6.7 %			18.2 %	1.3 x	7.9 x
Home Care / Hospice (4)							
Amedisys, Inc. (NasdaqGS:AMED)	\$4,030.1	9.5 %	\$1,662.6	\$168.4	10.1 %	2.4 x	23.9 x
LHC Group, Inc. (NasdaqGS:LHCG)	3,536.9	31.4	1,810.0	164.7	9.1	2.0	21.5
Addus HomeCare Corporation (NasdaqGS:ADUS)	787.0	15.9	517.8	39.2	7.6	1.5	20.1
BioScrip, Inc. (NasdaqGS:BIOS)	711.8	(10.3)	708.9	41.0	5.8	1.0	17.4
Median		12.7 %			8.3 %	1.7 x	20.8 x

LSHC sector breakdown: financial detail (cont.)⁽¹⁾


	Enterprise value (\$MM)	Three-year revenue CAGR	LTM			EV / LTM	
			Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA
Data/Analytics (3)							
Inovalon Holdings, Inc. (NasdaqGS:INOV)	\$2,639.5	6.5 %	\$527.7	\$117.5	22.3 %	5.0 x	22.5 x
National Research Corporation (NasdaqGS:NRC)	1,013.1	5.4	119.7	40.8	34.1	8.5	24.8
Castlight Health, Inc. (NYSE:CSLT)	464.6	27.6	156.4	(32.9)	NA	3.0	NA
Median		6.5 %			28.2 %	5.0 x	23.7 x
Tech-Enabled Services (9)							
Cerner Corporation (NasdaqGS:CERN)	\$20,038.2	7.2 %	\$5,366.3	\$1,207.1	22.5 %	3.7 x	16.6 x
Veeva Systems Inc. (NYSE:VEEV)	18,640.7	28.2	862.2	236.9	27.5	21.6	78.7
HealthEquity, Inc. (NasdaqGS:HQY)	4,245.2	31.3	287.2	95.9	33.4	14.8	44.3
Omnicell, Inc. (NasdaqGS:OMCL)	3,401.9	17.6	787.3	83.2	10.6	4.3	40.9
HMS Holdings Corp. (NasdaqGS:HMSY)	2,619.2	8.1	598.3	132.2	22.1	4.4	19.8
Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX)	2,134.8	8.1	1,750.0	69.8	4.0	1.2	30.6
Premier Foods plc (LSE:PFD)	1,052.4	2.3	1,074.8	150.0	14.0	1.0	7.0
NextGen Healthcare, Inc. (NasdaqGS:NXGN)	1,170.4	2.5	530.2	38.9	7.3	2.2	30.1
Computer Programs and Systems, Inc. (NasdaqGS:CPSI)	539.9	15.5	280.4	34.1	12.2	1.9	15.8
Median		8.1 %			14.0 %	3.7 x	30.1 x
Biotechnology (7)							
AbbVie Inc. (NYSE:ABBV)	\$151,655.1	12.7 %	\$32,753.0	\$13,676.0	41.8 %	4.6 x	11.1 x
Amgen Inc. (NasdaqGS:AMGN)	123,741.5	3.1	23,747.0	12,497.0	52.6	5.2	9.9
Celgene Corporation (NasdaqGS:CELG)	80,340.8	18.2	15,281.0	6,124.0	40.1	5.3	13.1
Gilead Sciences, Inc. (NasdaqGS:GILD)	79,836.2	(12.2)	22,127.0	10,449.0	47.2	3.6	7.6
Biogen Inc. (NasdaqGS:BIIB)	48,526.7	7.7	13,452.9	7,025.5	52.2	3.6	6.9
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN)	39,564.2	17.8	6,710.8	2,682.6	40.0	5.9	14.7
Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)	32,190.4	16.6	4,131.2	1,999.8	48.4	7.8	16.1
Median		12.7 %			47.2 %	5.2 x	11.1 x
Contract Research and Manufacturing (8)							
IQVIA Holdings Inc. (NYSE:IQV)	\$38,102.4	34.0 %	\$10,412.0	\$1,795.0	17.2 %	3.7 x	21.2 x
Charles River Laboratories International, Inc. (NYSE:CRL)	8,435.1	18.5	2,266.1	520.9	23.0	3.7	16.2
West Pharmaceutical Services, Inc. (NYSE:WST)	8,395.3	7.1	1,717.4	355.3	20.7	4.9	23.6
Syneos Health, Inc. (NasdaqGS:SYNH)	7,863.7	68.7	4,390.1	549.5	12.5	1.8	14.3
PRA Health Sciences, Inc. (NasdaqGS:PRAH)	7,596.8	27.8	2,871.9	428.7	14.9	2.6	17.7
ICON Public Limited Company (NasdaqGS:ICLR)	7,292.5	18.1	2,595.8	451.8	17.4	2.8	16.1
Medpace Holdings, Inc. (NasdaqGS:MEDP)	2,180.1	30.1	704.6	139.8	19.8	3.1	15.6
Cambrex Corporation (NYSE:CBM)	1,486.7	7.0	531.2	148.8	28.0	2.8	10.0
Median		23.1 %			18.6 %	3.0 x	16.2 x
Pharmaceuticals (4)							
Pfizer Inc. (NYSE:PFE)	\$254,758.8	3.2 %	\$53,647.0	\$22,058.0	41.1 %	4.7 x	11.5 x
Merck & Co., Inc. (NYSE:MRK)	221,357.3	2.3	42,294.0	13,095.0	31.0	5.2	16.9
Eli Lilly and Company (NYSE:LLY)	124,160.5	7.2	24,555.7	7,872.2	32.1	5.1	15.8
Bristol-Myers Squibb Company (NYSE:BMJ)	72,864.9	10.9	22,561.0	6,984.0	31.0	3.2	10.4
Median		5.2 %			31.5 %	4.9 x	13.7 x
Tools and Services (8)							
Abbott Laboratories (NYSE:ABT)	\$152,502.2	14.4 %	\$30,578.0	\$7,200.0	23.5 %	5.0 x	21.2 x
Thermo Fisher Scientific Inc. (NYSE:TMO)	128,996.4	12.8	24,358.0	6,156.0	25.3	5.3	21.0
Becton, Dickinson and Company (NYSE:BDX)	86,503.6	15.0	17,063.0	5,084.0	29.8	5.1	17.0
illumina, Inc. (NasdaqGS:ILMN)	48,200.1	14.5	3,333.0	1,062.0	31.9	14.5	45.4
Agilent Technologies, Inc. (NYSE:A)	25,453.4	7.3	4,987.0	1,201.0	24.1	5.1	21.2
Waters Corporation (NYSE:WAT)	17,354.2	5.8	2,419.9	847.8	35.0	7.2	20.5
PerkinElmer, Inc. (NYSE:PKI)	12,807.6	9.7	2,778.0	559.3	20.1	4.6	22.9
Bio-Rad Laboratories, Inc. (NYSE:BIO)	8,838.9	4.3	2,289.4	327.0	14.3	3.9	27.0
Median		11.3 %			24.7 %	5.1 x	21.2 x
Commercial Plans (5)							
UnitedHealth Group Incorporated (NYSE:UNH)	\$239,876.2	12.9 %	\$226,247.0	\$19,166.0	8.5 %	1.1 x	12.5 x
Cigna Corporation (NYSE:CI)	99,660.5	8.6	48,569.0	5,208.0	10.7	2.1	19.1
Anthem, Inc. (NYSE:ANTM)	80,927.5	5.2	92,091.0	6,363.0	6.9	0.9	12.7
Humana Inc. (NYSE:HUM)	38,255.4	1.6	56,912.0	3,336.0	5.9	0.7	11.5
Magellan Health, Inc. (NasdaqGS:MGLN)	2,171.2	16.7	7,314.2	149.0	2.0	0.3	14.6
Median		8.6 %			6.9 %	0.9 x	12.7 x
Government Plans (3)							
Centene Corporation (NYSE:CNC)	\$23,305.0	38.6 %	\$56,688.0	\$2,627.0	4.6 %	0.4 x	8.9 x
WellCare Health Plans, Inc. (NYSE:WCG)	12,071.2	13.7	20,414.1	920.7	4.5	0.6	13.1
Molina Healthcare, Inc. (NYSE:MOH)	6,735.6	10.3	18,144.0	1,249.0	6.9	0.4	5.4
Median		13.7 %			4.6 %	0.4 x	8.9 x
Payor Services (1)							
CorVel Corporation (NasdaqGS:CRVL)	\$1,165.9	5.7 %	\$588.2	\$79.8	13.6 %	2.0 x	14.6 x
Median		5.7 %			13.6 %	2.0 x	14.6 x

LSHC sector breakdown: financial detail (cont.)⁽¹⁾


	Enterprise value (\$MM)	Three-year revenue CAGR	LTM			EV / LTM		
			Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA	
Pharmacy	Retail Pharmacy (3)							
	CVS Health Corporation (NYSE:CVS)	\$134,892.9	8.2 %	\$193,919.0	\$12,431.0	6.4 %	0.7 x	10.9 x
	Walgreens Boots Alliance, Inc. (NasdaqGS:WBA)	68,972.8	5.3	136,097.0	7,675.0	5.6	0.5	9.0
	Rite Aid Corporation (NYSE:RAD)	3,845.4	1.4	21,639.6	459.9	2.1	0.2	8.4
Median		5.3 %			5.6 %	0.5 x	9.0 x	
Pharmacy	Specialty Pharmacy (1)							
	Diplomat Pharmacy, Inc. (NYSE:DPLO)	998.8	17.7	5,492.5	118.1	2.2	0.2	8.5
Median		17.7 %			2.2 %	0.2 x	8.5 x	
Physicians / Staffing	Healthcare Staffing (2)							
	ASGN Incorporated (NYSE:ASGN)	\$4,652.8	18.1 %	\$3,399.8	\$371.7	10.9 %	1.4 x	12.5 x
	AMN Healthcare Services, Inc. (NYSE:AMN)	2,624.3	13.4	2,136.1	253.8	11.9	1.2	10.3
	Cross Country Healthcare, Inc. (NasdaqGS:CCRN)	318.3	2.1	816.5	27.1	3.3	0.4	11.7
Median		13.4 %			10.9 %	1.2 x	11.7 x	
Physicians / Staffing	Physician Practice Management (1)							
	MEDNAX, Inc. (NYSE:MD)	4,133.0	9.5	3,647.1	557.1	15.3	1.1	7.4
Median		9.5 %			15.3 %	1.1 x	7.4 x	
Medical Devices and Products	Medical Devices and Products (15)							
	Johnson & Johnson (NYSE:JNJ)	\$381,068.8	5.1 %	\$81,593.0	\$27,940.3	34.2 %	4.7 x	13.6 x
	Medtronic plc (NYSE:MDT)	129,546.8	2.4	30,555.0	9,676.0	31.7	4.2	13.4
	Danaher Corporation (NYSE:DHR)	98,006.3	11.3	19,893.0	4,818.5	24.2	4.9	20.3
	Stryker Corporation (NYSE:SYK)	73,785.3	11.0	13,601.0	3,817.0	28.1	5.4	19.3
	Boston Scientific Corporation (NYSE:BSX)	55,704.9	9.5	9,823.0	2,618.0	26.7	5.7	21.3
	Baxter International Inc. (NYSE:BAX)	39,569.9	3.7	11,127.0	2,585.0	23.2	3.6	15.3
	Edwards Lifesciences Corporation (NYSE:EW)	37,138.6	14.3	3,722.8	1,150.0	30.9	10.0	32.3
	Zimmer Biomet Holdings, Inc. (NYSE:ZBH)	32,915.2	9.8	7,932.9	2,380.6	30.0	4.1	13.8
	Hologic, Inc. (NasdaqGS:HOLX)	15,506.3	5.8	3,257.5	1,022.0	31.4	4.8	15.2
	Teleflex Incorporated (NYSE:TFX)	14,619.8	10.8	2,448.4	666.6	27.2	6.0	21.9
	ResMed Inc. (NYSE:RMD)	15,075.6	12.1	2,454.6	736.5	30.0	6.1	20.5
	DENTSPLY SIRONA Inc. (NasdaqGS:XRAY)	12,257.4	14.2	3,986.3	672.7	16.9	3.1	18.2
	Varian Medical Systems, Inc. (NYSE:VAR)	11,313.8	0.1	2,981.6	561.6	18.8	3.8	20.1
	STERIS plc (NYSE:STE)	11,201.5	10.2	2,729.9	634.1	23.2	4.1	17.7
	Hill-Rom Holdings, Inc. (NYSE:HRC)	8,221.1	9.4	2,861.8	571.0	20.0	2.9	14.4
Integer Holdings Corporation (NYSE:ITGR)	3,208.6	14.9	1,215.0	255.5	21.0	2.6	12.6	
Median		10.0 %			26.9 %	4.5 x	17.9 x	
Medical Supplies Distribution	Medical Supplies Distribution (7)							
	McKesson Corporation (NYSE:MCK)	\$29,601.4	4.1 %	\$213,518.0	\$4,099.0	1.9 %	0.1 x	7.2 x
	Cardinal Health, Inc. (NYSE:CAH)	20,274.8	8.1	141,935.0	2,870.0	2.0	0.1	7.1
	AmerisourceBergen Corporation (NYSE:ABC)	17,402.9	7.5	172,865.8	2,159.1	1.2	0.1	8.1
	Henry Schein, Inc. (NasdaqGS:HSIC)	11,090.9	7.5	13,202.0	1,100.8	8.3	0.8	10.1
	Patterson Companies, Inc. (NasdaqGS:PDCO)	2,641.1	3.7	5,538.4	215.8	3.9	0.5	12.2
	Owens & Minor, Inc. (NYSE:OMI)	1,781.9	0.2	9,838.7	225.9	2.3	0.2	7.9
Median		5.8 %			2.2 %	0.2 x	8.0 x	

LSHC sector data


US health care spend⁽¹⁾




US health care spend by payor per capita^{(2) (i)}




US population by age group⁽³⁾



Number of US uninsured by age group⁽⁴⁾



Annual LSHC M&A transactions by transaction size⁽⁵⁾



Note:

i) CAGR listed represents total Medicare, Medicaid and Private Health Insurance.

Sources cited

Page 2:

1. Alison Hagan, Casey Graves, Dan Kinsella, and Wendy Gerhardt, Shifting into high gear: Health systems have a growing strategic focus on analytics today for the future, Deloitte Insights. 2019. https://www2.deloitte.com/content/dam/insights/us/articles/4897_Health-system-analytics-revisited/DI_Health-system-analytics.pdf, accessed April 14, 2019.
2. Ibid.
3. Ibid.
4. Ibid.
5. Pharmagest Interactive, "PHARMAGEST acquires 15% stake of French-american Start-up Embleema." *Global News Wire*, January 7, 2019. <https://www.globenewswire.com/news-release/2019/01/07/1681562/0/en/PHARMAGEST-acquires-15-stake-of-French-american-Start-up-Embleema.html>, accessed April 14, 2019.
6. Prakash Ramachandran, "Digital Reasoning Announces Strategic Investment" *Digital Reasoning*, February, 13, 2019. <https://digitalreasoning.com/blog/digital-reasoning-announces-strategic-investment-from-macquarie-group-in-new-partnership/>, accessed April 14, 2019.

Page 3:

1. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.
2. Ibid.

Page 4:

1. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.

Page 5:

1. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.

Page 6:

1. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.

Page 7:

1. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.

Page 8:

1. "National Health Expenditures and Selected Economic Indicators," *Centers for Medicare & Medicaid, Office of the Actuary*. 2019.
2. Ibid.
3. "Population by Age and Sex," *U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement*. April 2019.
4. "Early Release of Selected Estimates Based on Data From the 2016 National Health Interview Survey," *U.S. Department of Health and Human Services*. April 2019.
5. S&P Capital IQ, <https://www.capitaliq.com>, accessed April 14, 2019. Data as of April 14, 2019.

Deloitte Corporate Finance LLC (DCF)

DCF provides deal execution and lead financial advisory services to large corporate, middle market, private equity and venture capital firms. DCF and its affiliates maintain a presence in key US financial centers.

For additional information or to find out more about how DCF can assist the deal initiation and execution process, please contact one of our DCF managing directors:

Phil Colaco, CEO
philcolaco@deloitte.com

+1 704 333 0533

Nick Cirignano
nicirignano@deloitte.com

+1 212 436 3273

Jamie Lewin
jlewin@deloitte.com

+1 214 840 7057

Matt Preece
mpreece@deloitte.com

+1 704 731 7186

Jonathan Adams
[jonadams@deloitte.com](mailto:jnadams@deloitte.com)

+1 214 840 1779

John Deering
jdeering@deloitte.com

+1 704 333 0574

James Miller
jamesmiller5@deloitte.com

+1 704 731 8230

Ron Rivera
rorivera@deloitte.com

+1 404 631 3710

Keith Adams
keadams@deloitte.com

+1 404 631 3455

Lorin DeMordaunt
ldemordaunt@deloitte.com

+1 704 333 0591

Byron Nelson
bynelson@deloitte.com

+1 469 417 2462

Justin Silber
jsilber@deloitte.com

+1 404 942 6960

Eric Andreozzi
eandreozi@deloitte.com

+1 704 333 0518

Will Frame
wframe@deloitte.com

+1 312 486 4458

Jonathan Ohm
johm@deloitte.com

+1 212 436 2287

Tom Spivey
tspivey@deloitte.com

+1 214 840 7014

Tony Blanchard
anblanchard@deloitte.com

+1 313 396 3738

Mike Garcia
migarcia@deloitte.com

+1 213 996 4901

Lou Paone
lpaone@deloitte.com

+1 704 731 7202

Vijay Balasubramanian
vbalasubramanian@deloitte.com

+1 212 313 1723

Doug Bolt
dbolt@deloitte.com

+1 704 731 7219

Simon Gisby
sgisby@deloitte.com

+1 212 436 2495

Jason Porter
[jasporter@deloitte.com](mailto:jasperporter@deloitte.com)

+1 704 333 0136

Charlie Welch
charliewelch@deloitte.com

+1 704 731 7201

Hector Calzada
hcalzada@deloitte.com

+1 404 631 3015

Bill Kerkam
wkerkam@deloitte.com

+1 980 312 3613

Garett Poston
gposton@deloitte.com

+1 213 593 4544

Deloitte Corporate Finance Business Development Group:

Brad Heston

Senior Vice President
bheston@deloitte.com

+1 404 631 3839

John Lindsey

Senior Vice President
jlindsey@deloitte.com

+1 469 417 2147

Bill Pucci

Senior Vice President
wpucci@deloitte.com

+1 973 602 4542

www.investmentbanking.deloitte.com

Deloitte.

This newsletter is a periodic compilation of certain completed and announced merger and acquisition activity. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have "long" and "short" positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

About Deloitte

Deloitte Corporate Finance LLC (DCF), a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and member of the [Financial Industry Regulatory Authority \(FINRA\)](#) and the [Securities Investor Protection Corporation \(SIPC\)](#), is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking or other services that would require registration as a broker-dealer with the SEC and membership in FINRA would be provided exclusively by DCF. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Copyright © 2019 Deloitte Development LLC. All rights reserved.